The Tumor-on-a-chip ecosystem comprises a coordinated set of upstream, midstream, and downstream activities that transform raw materials into actionable pre‑clinical insights. Upstream, raw material and component suppliers deliver polymers, silicon wafers, and surface treatments required for microfabricated chips. Midstream, technology providers create microfluidic architectures, integrate biosensors, and standardize organoid culture methods, which are then assembled by system integrators into complete platforms. Downstream, distributors and channel partners bring these platforms to research laboratories, while service providers ensure operational reliability through calibration and training. End users—pharma companies, academic labs, and contract research organizations—run assays that generate biological data, which is subsequently processed by data‑analytics providers. Value is captured through licensing of proprietary designs, platform sales, and recurring service contracts.